Human neural stem cells (NSCs) are particularly valuable for the study of neurogenesis process and have a therapeutic potential in treating neurodegenerative disorders. However, current progress in the use of human NSCs is limited due to the available NSC sources and the complicated isolation and culture techniques. In this study, we describe an efficient method to isolate and propagate human NSCs from the amniotic fluid with diagnosed neural tube defects (NTDs), specifically, anencephaly. These amniotic fluid-derived NSCs (AF-NSCs) formed neurospheres and underwent long-term expansion in vitro. In addition, these cells showed normal karyotypes and telomerase activity and expressed NSC-specific markers, including Nestin, Sox2, Musashi-1, and the ATP-binding cassette G2 (ABCG2). AF-NSCs displayed typical morphological patterns and expressed specific markers that were consistent with neurons, astrocytes, oligodendrocytes, and dopaminergic neurons after proper induction conditions. Furthermore, grafted AF-NSCs improved the physiological functions in a rat stroke model. The ability to isolate and bank human NSCs from this novel source provides a unique opportunity for translational studies of neurological disorders.
Get full access to this article
View all access options for this article.
References
1.
OkanoH. (2002). Neural stem cells: progression of basic research and perspective for clinical application. Keio J Med, 51:115–128.
2.
ReynoldsBA and WeissS. (1992). Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science, 255:1707–1710.
3.
KordowerJH, FreemanTB, SnowBJ, VingerhoetsFJ, MufsonEJ, SanbergPR, HauserRA, SmithDA, NauertGM, PerlDP, et al. (1995). Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med, 332:1118–1124.
4.
HwangDH, LeeHJ, ParkIH, SeokJI, KimBG, JooIS and KimSU. (2009). Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther, 16:1234–1244.
5.
AndresRH, HorieN, SlikkerW, Keren-GillH, ZhanK, SunG, ManleyNC, PereiraMP, SheikhLA, et al. (2011). Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain. Brain, 134:1777–1789.
6.
AbematsuM, TsujimuraK, YamanoM, SaitoM, KohnoK, KohyamaJ, NamihiraM, KomiyaS and NakashimaK. (2010). Neurons derived from transplanted neural stem cells restore disrupted neuronal circuitry in a mouse model of spinal cord injury. J Clin Invest, 120:3255–3266.
7.
Gonzalez-PerezO. (2012). Neural stem cells in the adult human brain. Biol Biomed Rep, 2:59–69.
8.
SchwartzPH, BryantPJ, FujaTJ, SuH, O'DowdDK and KlassenH. (2003). Isolation and characterization of neural progenitor cells from post-mortem human cortex. J Neurosci Res, 74:838–851.
9.
VescoviAL, ParatiEA, GrittiA, PoulinP, FerrarioM, WankeE, Frolichsthal-SchoellerP, CovaL, Arcellana-PanlilioM, ColomboA and GalliR. (1999). Isolation and cloning of multipotential stem cells from the embryonic human CNS and establishment of transplantable human neural stem cell lines by epigenetic stimulation. Exp Neurol, 156:71–83.
10.
EarlCD, ReumT, XieJX, SautterJ, KupschA, OertelWH and MorgensternR. (1996). Foetal nigral cell suspension grafts influence dopamine release in the non-grafted side in the 6-hydroxydopamine rat model of Parkinson's disease: in vivo voltammetric data. Exp Brain Res, 109:179–184.
11.
RyderEF, SnyderEY and CepkoCL. (1990). Establishment and characterization of multipotent neural cell lines using retrovirus vector-mediated oncogene transfer. J Neurobiol, 21:356–375.
12.
De FilippisL, FerrariD, Rota NodariL, AmatiB, SnyderE and VescoviAL. (2008). Immortalization of human neural stem cells with the c-myc mutant T58A. PLoS One, 3:e3310.
13.
ZhangSC, WernigM, DuncanID, BrustleO and ThomsonJA. (2001). In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol, 19:1129–1133.
14.
ReubinoffBE, ItsyksonP, TuretskyT, PeraMF, ReinhartzE, ItzikA and Ben-HurT. (2001). Neural progenitors from human embryonic stem cells. Nat Biotechnol, 19:1134–1140.
15.
ChambersSM, FasanoCA, PapapetrouEP, TomishimaM, SadelainM and StuderL. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol, 27:275–280.
16.
MiuraK, OkadaY, AoiT, OkadaA, TakahashiK, OkitaK, NakagawaM, KoyanagiM, TanabeK, et al. (2009). Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol, 27:743–745.
17.
BottoLD, MooreCA, KhouryMJ and EricksonJD. (1999). Neural-tube defects. N Engl J Med, 341:1509–1519.
18.
CoppAJ and GreeneND. (2010). Genetics and development of neural tube defects. J Pathol, 220:217–230.
19.
CoppAJ, StanierP and GreeneND. (2013). Neural tube defects: recent advances, unsolved questions, and controversies. Lancet Neurol, 12:799–810.
20.
YamaguchiY and MiuraM. (2013). How to form and close the brain: insight into the mechanism of cranial neural tube closure in mammals. Cell Mol Life Sci, 70:3171–3186.
21.
KennedyD, ChitayatD, WinsorEJ, SilverM and ToiA. (1998). Prenatally diagnosed neural tube defects: ultrasound, chromosome, and autopsy or postnatal findings in 212 cases. Am J Med Genet, 77:317–321.
22.
WaldN, CuckleH and NanchahalK. (1989). Amniotic fluid acetylcholinesterase measurement in the prenatal diagnosis of open neural tube defects. Second report of the Collaborative Acetylcholinesterase Study. Prenat Diagn, 9:813–829.
23.
TsaiMS, LeeJL, ChangYJ and HwangSM. (2004). Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod, 19:1450–1456.
24.
De CoppiP, BartschGJr., SiddiquiMM, XuT, SantosCC, PerinL, MostoslavskyG, SerreAC, SnyderEY, et al. (2007). Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol, 25:100–106.
25.
PrusaAR, MartonE, RosnerM, BettelheimD, LubecG, PollackA, BernaschekG and HengstschlagerM. (2004). Neurogenic cells in human amniotic fluid. Am J Obstet Gynecol, 191:309–314.
26.
SwistowskiA, PengJ, LiuQ, MaliP, RaoMS, ChengL and ZengX. (2010). Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells, 28:1893–1904.
27.
LongaEZ, WeinsteinPR, CarlsonS and CumminsR. (1989). Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke, 20:84–91.
28.
TurnerCG, KleinJD, WangJ, ThakorD, BenedictD, AhmedA, TengYD and FauzaDO. (2013). The amniotic fluid as a source of neural stem cells in the setting of experimental neural tube defects. Stem Cells Dev, 22:548–553.
29.
PenningtonEC, GrayFL, AhmedA, ZurakowskiD and FauzaDO. (2013). Targeted quantitative amniotic cell profiling: a potential diagnostic tool in the prenatal management of neural tube defects. J Pediatr Surg, 48:1205–1210.
30.
ReynoldsBA and RietzeRL. (2005). Neural stem cells and neurospheres—re-evaluating the relationship. Nat Methods, 2:333–336.
31.
OstenfeldT, CaldwellMA, ProwseKR, LinskensMH, JauniauxE and SvendsenCN. (2000). Human neural precursor cells express low levels of telomerase in vitro and show diminishing cell proliferation with extensive axonal outgrowth following transplantation. Exp Neurol, 164:215–226.
32.
JensenJB and ParmarM. (2006). Strengths and limitations of the neurosphere culture system. Mol Neurobiol, 34:153–161.
33.
TropepeV, SibiliaM, CirunaBG, RossantJ, WagnerEF and van der KooyD. (1999). Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev Biol, 208:166–188.
34.
MorsheadCM and van der KooyD. (2004). Disguising adult neural stem cells. Curr Opin Neurobiol, 14:125–131.
35.
XiongF, GaoH, ZhenY, ChenX, LinW, ShenJ, YanY, WangX, LiuM and GaoY. (2011). Optimal time for passaging neurospheres based on primary neural stem cell cultures. Cytotechnology, 63:621–631.
36.
SunY, KongW, FalkA, HuJ, ZhouL, PollardS and SmithA. (2009). CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS One, 4:e5498.
37.
BauerHC, TempferH, BernroiderG and BauerH. (2006). Neuronal stem cells in adults. Exp Gerontol, 41:111–116.
38.
CapelaA and TempleS. (2002). LeX/ssea-1 is expressed by adult mouse CNS stem cells, identifying them as nonependymal. Neuron, 35:865–875.
39.
TsaiMS, HwangSM, TsaiYL, ChengFC, LeeJL and ChangYJ. (2006). Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod, 74:545–551.
ZhangP, LiJ, LiuY, ChenX, KangQ, ZhaoJ and LiW. (2009). Human neural stem cell transplantation attenuates apoptosis and improves neurological functions after cerebral ischemia in rats. Acta Anaesthesiol Scand, 53:1184–1191.
42.
ChenB, GaoXQ, YangCX, TanSK, SunZL, YanNH, PangYG, YuanM, ChenGJ, et al. (2009). Neuroprotective effect of grafting GDNF gene-modified neural stem cells on cerebral ischemia in rats. Brain Res, 1284:1–11.
43.
MonniE, CusulinC, CavallaroM, LindvallO and KokaiaZ. (2014). Human fetal striatum-derived neural stem (ns) cells differentiate to mature neurons in vitro and in vivo. Curr Stem Cell Res Ther, 9:338–346.
44.
BlissT, GuzmanR, DaadiM and SteinbergGK. (2007). Cell transplantation therapy for stroke. Stroke, 38:817–826.
45.
RosnerM and HengstschlagerM. (2013). Amniotic fluid stem cells and fetal cell microchimerism. Trends Mol Med, 19:271–272.
46.
RosnerM, DolznigH, SchipanyK, MikulaM, BrandauO and HengstschlagerM. (2011). Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis. Oncotarget, 2:705–712.
47.
HosperNA, BankRA and van den BergPP. (2014). Human amniotic fluid-derived mesenchymal cells from fetuses with a neural tube defect do not deposit collagen type i protein after TGF-beta1 stimulation in vitro. Stem Cells Dev, 23:555–562.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
